What We Enable
Multi-Organ Integration
Connect liver, kidney, heart, lung, brain, and gut models for comprehensive systemic drug response prediction across organ systems.
Patient-Specific Modeling
iPSC-derived organoids and digital twins enable truly personalized drug testing on patient-derived cells with individual genetic backgrounds.
Real-Time Analytics
Continuous monitoring and AI-powered analysis of biological responses across experimental timescales with instant insights.
Regulatory Alignment
Data outputs designed for FDA Modernization Act 3.0 compliance, ICH guidelines, and seamless regulatory submission.
Platform Metrics
More Capabilities
High-Throughput Screening
Automated platforms supporting 384-well and 1536-well formats for rapid compound evaluation at scale.
Biomarker Discovery
AI-driven identification of novel biomarkers predictive of drug response and disease progression.
Toxicity Prediction
Multi-endpoint toxicity screening across hepatotoxicity, cardiotoxicity, nephrotoxicity, and neurotoxicity.
Drug-Drug Interactions
Model complex polypharmacy scenarios with metabolic pathway interactions and competitive inhibition.
Disease Modeling
Patient-derived disease models for oncology, neurodegeneration, metabolic disorders, and rare diseases.
ADME Profiling
Comprehensive absorption, distribution, metabolism, and excretion studies with human-relevant systems.
Explore Use Cases
See how these capabilities translate to real-world drug discovery applications.
View Use Cases